[Toxic epidermal necrolysis associated with abacavir].
Montero
Milagro
M
García-Gibert
Lidia
L
Giménez-Arnau
Ana María
AM
Knobel
Hernando
H
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D016049:Didanosine / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D000099227:Abacavir
D019380:Anti-HIV Agents; D016049:Didanosine; D015224:Dideoxynucleosides; D019829:Nevirapine; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D000099227:Abacavir